Billy W. Loo Jr, MD, PhD
On its own, stereotactic ablative radiotherapy (SABR) has been established in the field as a go-to radiation option for patients with lung cancer, especially in those with oligometastatic disease, explains Billy W. Loo Jr, MD, PhD.
on Advanced Non–Small Cell Lung Cancer.
OncLive: Please provide an overview of your presentation.
I talked about one particular development in RT, which is ablative radiotherapy—SABR—and some of the indications, how it developed first for treatment of early-stage lung cancer for patients primarily who were not candidates for surgery, and how additional emerging indications have come out. These include RT for certain patients with metastatic disease.
... to read the full story